文献速递心外重症与机械循环支持

左心室辅助装置植入对二尖瓣反流的影响:MOMENTUM 3 试验分析

Impact of left ventricular assist device implantation on mitral regurgitation: An analysis from the MOMENTUM 3 trial.
PubMed 文献 · J Heart Lung Transplant · 2020-03-20

基于 MOMENTUM 3 试验中 927 例无二尖瓣手术史的 LVAD 植入患者,43.5% 基线存在中度或重度二尖瓣反流(MR)。HM3 组术后 1 月残余 MR 为 6.2%,低于 HMII 组的 14.3%(RR=0.43,95%CI 0.22-0.84,p=0.01)。基线及残余 MR 均未影响 2 年死亡率、主要不良事件或功能容量。

要点

  • LVAD 植入后临床显著 MR 早期即改善,HM3 残余 MR 低于 HMII。
  • 基线或术后 1 月残余 MR 均不影响 2 年死亡率及主要不良事件。
  • 基线重度 MR、左室尺寸较大及使用 HMII 与残余 MR 独立相关。

核心结论

  • LVAD 植入后血流动力学卸载可早期、持续改善临床显著 MR,HM3 改善程度大于 HMII。
  • 基线 MR 与残余 MR 均不影响 LVAD 植入后结局。

研究设计与样本

  • MOMENTUM 3 试验分析,纳入 927 例植入 HMII 或 HM3 且无既往或同期二尖瓣手术的患者,评估 2 年结局。
  • 临床显著 MR 定义为站点超声心动图确定的中度或重度 MR。

主要发现

  • 927 例中 403 例(43.5%)基线存在临床显著 MR。
  • 术后 1 月残余 MR 在 HM3 组为 6.2%,HMII 组为 14.3%(RR=0.43,95%CI 0.22-0.84,p=0.01)。
  • 残余 MR 与 2 年死亡率无关:HM3 组 HR=1.41(95%CI 0.52-3.89,p=0.50),HMII 组 HR=0.91(95%CI 0.37-2.26,p=0.84)。
  • 基线 MR 有无与死亡率无关:HM3 组 HR=0.86(95%CI 0.56-1.33,p=0.50),HMII 组 HR=0.81(95%CI 0.54-1.22,p=0.32)。
  • 基线 MR 有无未影响主要不良事件或功能容量。

关键数值与推荐

  • 临床显著 MR 定义为中度或重度 MR。
  • 多变量分析中,基线重度 MR(p=0.001)、左室尺寸较大(p=0.002)及植入 HMII 而非 HM3(p=0.05)与术后持续 MR 独立相关。

临床怎么用

  • LVAD 植入后无需因基线 MR 而额外干预二尖瓣,因 MR 早期改善且不影响生存。
  • HM3 对 MR 的改善优于 HMII,选择装置时可考虑此差异。

局限性

  • MR 评估基于站点超声心动图,非核心实验室统一判读。
  • 研究为 MOMENTUM 3 试验的事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mitral regurgitation (MR) determines pathophysiology and outcome in advanced heart failure. The impact of left ventricular assist device (LVAD) placement on clinically significant MR and its contribution to long-term outcomes has been sparsely evaluated. METHODS: We evaluated the effect of clinically significant MR on patients implanted in the MOMENTUM 3 trial with either the HeartMate II (HMII) or the HeartMate 3 (HM3) at 2 years. Clinical significance was defined as moderate or severe grade MR determined by site-based echocardiograms. RESULTS: Of 927 patients with LVAD implants without a prior or concomitant mitral valve procedure, 403 (43.5%) had clinically significant MR at baseline. At 1-month of support, residual MR was present in 6.2% of patients with HM3 and 14.3% of patients with HMII (relative risk = 0.43; 95% CI, 0.22-0.84; p = 0.01) with a low rate of worsening at 2 years. Residual MR at 1-month post-implant did not impact 2-year mortality for either the HM3 (hazard ratio [HR],1.41; 95% CI, 0.52-3.89; p = 0.50) or HMII (HR, 0.91; 95% CI, 0.37-2.26; p = 0.84) LVAD. The presence or absence of baseline MR did not influence mortality (HM3 HR, 0.86; 95% CI, 0.56-1.33; p = 0.50; HMII HR, 0.81; 95% CI, 0.54-1.22; p = 0.32), major adverse events or functional capacity. In multivariate analysis, severe baseline MR (p = 0.001), larger left ventricular dimension (p = 0.002), and implantation with the HMII instead of the HM3 LVAD (p = 0.05) were independently associated with an increased likelihood of persistent MR post-implant. CONCLUSIONS: Hemodynamic unloading after LVAD implantation improves clinically significant MR early, sustainably, and to a greater extent with the HM3 LVAD. Neither baseline nor residual MR influence outcomes after LVAD implantation.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Kanwar MK, Rajagopal K, Itoh A, et al. Impact of left ventricular assist device implantation on mitral regurgitation: An analysis from the MOMENTUM 3 trial. J Heart Lung Transplant. 2020. PMID: 32279919. doi:10.1016/j.healun.2020.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。